Between The Lakes Sleep And Airway Center Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1250 Teckla Pl, Kiel, WI 53042 Phone: 920-894-2305 |
Kiel Family Dental Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 403 Fremont St, Kiel, WI 53042 Phone: 920-898-2305 Fax: 920-894-3048 |
News Archive
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that results from a United States Pharmacopeia Preservative Efficacy Test (USP PET) qualified NexACT as an anti-microbial preservative. The results show that NexACT was effective in killing more than 23 strains of bacteria, fungus and mold, well beyond the requirements for passing the USP PET.
Gene therapy is the delivery of DNA into a patient's cells to replace faulty or missing genes—or adds new genes—in an attempt to cure cancer or make changes so the body is better able to fight off disease. Scientists and clinicians have identified a number of different ways to do this, in an effort to correct malfunctioning or mutated genes. Many gene therapy clinical trials are ongoing to assess the safety and potential benefits in patients with rare diseases.
In his emotional concession speech, Cuccinelli also noted the lopsided spending and vowed he would not give up on his fight against Democrats' national health care law. … From the outset, the campaign shaped up as a barometer of voters' moods and a test of whether a swing-voting state like Virginia would elect a tea party-style governor. Republicans bet a deeply conservative candidate would be their best shot at holding onto the governor's office, passing over a lieutenant governor for Cuccinelli, a crusader against the federal health care law (11/6).
GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, is pleased to announce that it is in the process of acquiring three promising new drug target patents that could generate over a billion dollar in royalty fees in the mid to long term.
› Verified 4 days ago